 | | Vol. 5.46 – 10 December, 2021 |
| |
|
|
| The authors investigated whether farnesoid X receptor (FXR) played a role in regulating iron hepatotoxicity and found that iron suppressed FXR expression and signaling in human and mouse hepatocytes as well as in mouse liver and intestine.
[Hepatology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The secreted protein growth and differentiation factor 1 (GDF1) was found to be closely associated with poor tumor differentiation. Overexpression of GDF1 suppressed cell proliferation but strongly enhanced tumor dissemination and metastasis.
[Nature Communications] |
|
|
|
| Hepatocyte-specific deletion of Mettl3 drove nonalcoholic fatty liver-to-NASH progression by increasing CD36-mediated hepatic free fatty acid uptake and CCL2-induced inflammation, which was due to increased chromatin accessibility in the promoter region of Cd36 and Ccl2.
[Nature Communications] |
|
|
|
| Human primary hepatocyte organoids and HepaRG spheroids showed more mature hepatocyte phenotype after adding fibronectin and fibrinogen to the culture system.
[Biomaterials] |
|
|
|
| Investigators found that circMED27 was significantly increased in hepatocellular carcinoma (HCC) serum, and higher levels of circMED27 were correlated with bad clinical characteristics and poor prognosis of patients with HCC.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Analysis of The Cancer Genome Atlas data and the authors’ tumor models after ionizing radiation treatment indicated that increased expression of pre-mRNA processing factor 19 was positively correlated with DNA damage repair.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Researchers uncovered a conserved Yki/YAP-Src42A/SRC positive feedback loop promoting tumor cell migration and provided SRC as a potential therapeutic target for YAP-driven metastatic tumors.
[Cell Death & Disease] |
|
|
|
| Scientists demonstrated that stiffness contributed to mechanosignal transduction in hepatic stellate cells, which promoted hepatocellular carcinoma cells growth and metastasis through secretion of FGF2.
[Cell Death & Disease] |
|
|
|
| Investigators elucidated the role of miR-200c in cholestasis-induced biliary liver fibrosis and cholangiocyte activation, identifying sestrin 1 (SESN1) as a target of miR-200c.
[Laboratory Investigation] |
|
|
|
| Researchers investigated the molecular mechanisms underlying the effect of berberine against liver fibrogenesis in thioacetamide and carbon tetrachloride induced mouse liver fibrosis.
[Cell Death Discovery] |
|
|
|
| Scientists explored the potential role of integrator complex subunit 8 (INTS8) as a novel diagnostic or therapeutic target in intrahepatic cholangiocarcinoma.
[Scientific Reports] |
|
|
|
| The authors investigated miR1908-5p function by leveraging human primary hepatocytes and HuH-7 hepatoma models and implicated miR1908-5p in metabolic and energy regulation in hepatocyte models via multiple, independent, pathways.
[Scientific Reports] |
|
|
|
| Investigators characterized hepatic stellate cells obtained from patients carrying the wild type and the heterozygous or homozygous PNPLA3 I148M and investigated the effect of genotype and PNPLA3 downregulation on baseline and TGF-β-stimulated fibrotic gene expression.
[PLoS One] |
|
|
|
|
| Scientists describe advances in preclinical models for non-alcoholic fatty liver disease-non-alcoholic steatohepatitis, the recent introduction of novel technologies in this space, and their importance for drug discovery endeavors in the future.
[iScience] |
|
|
|
| The author discusses molecular mechanisms of gut microbiome–related hepatocarcinogenesis and the impact of dysbiosis on chronic liver disease progression.
[Journal of Gastrointestinal Cancer] |
|
|
|
|
| Hepion Pharmaceuticals, Inc. announced that the US FDA has granted Fast Track designation for the company’s lead drug candidate, CRV431, for the treatment of non-alcoholic steatohepatitis (NASH).
[Hepion Pharmaceuticals, Inc.] |
|
|
|
| SOTIO Biotech announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® in patients with selected advanced/refractory solid tumors in the Phase II AURELIO-04 study.
[SOTIO Biotech] |
|
|
|
|
| January 21 -23, 2022
Austin, Texas, United States |
|
|
|
|
|
| National Institutes of Health – Bethesda, Maryland, United States |
|
|
|
| | University of Gothenburg РG̦teborg, Sweden |
|
|
|
| | Accession Therapeutics – Oxford, England, United Kingdom |
|
|
|
| KU Leuven – Leuven, Belgium |
|
|
|
| | German Research Center for Environmental Health – Oberschleißheim, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
